118 related articles for article (PubMed ID: 38047781)
1. Late Microaerobic Growth for Efficient Production of Human Cytochrome P450 3A4 in E. coli.
Marchetti L; Planchestainer M; Panke S; Held M
Chimia (Aarau); 2023 Jun; 77(6):417-423. PubMed ID: 38047781
[TBL] [Abstract][Full Text] [Related]
2. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli.
Vail RB; Homann MJ; Hanna I; Zaks A
J Ind Microbiol Biotechnol; 2005 Feb; 32(2):67-74. PubMed ID: 15739102
[TBL] [Abstract][Full Text] [Related]
3. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5.
Yamazaki H; Johnson WW; Ueng YF; Shimada T; Guengerich FP
J Biol Chem; 1996 Nov; 271(44):27438-44. PubMed ID: 8910324
[TBL] [Abstract][Full Text] [Related]
4. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme.
Gillam EM; Baba T; Kim BR; Ohmori S; Guengerich FP
Arch Biochem Biophys; 1993 Aug; 305(1):123-31. PubMed ID: 8342945
[TBL] [Abstract][Full Text] [Related]
5. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates.
Yamazaki H; Ueng YF; Shimada T; Guengerich FP
Biochemistry; 1995 Jul; 34(26):8380-9. PubMed ID: 7599128
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities.
Gillam EM; Guo Z; Ueng YF; Yamazaki H; Cock I; Reilly PE; Hooper WD; Guengerich FP
Arch Biochem Biophys; 1995 Mar; 317(2):374-84. PubMed ID: 7893152
[TBL] [Abstract][Full Text] [Related]
7. Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms.
Perret A; Pompon D
Biochemistry; 1998 Aug; 37(33):11412-24. PubMed ID: 9708976
[TBL] [Abstract][Full Text] [Related]
8. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
9. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.
Shet MS; Fisher CW; Holmans PL; Estabrook RW
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11748-52. PubMed ID: 8265621
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.
Lin HL; Zhang H; Medower C; Hollenberg PF; Johnson WW
Drug Metab Dispos; 2011 Feb; 39(2):345-50. PubMed ID: 21068193
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.
Lightning LK; Jones JP; Friedberg T; Pritchard MP; Shou M; Rushmore TH; Trager WF
Biochemistry; 2000 Apr; 39(15):4276-87. PubMed ID: 10757976
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
Labroo RB; Paine MF; Thummel KE; Kharasch ED
Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
[TBL] [Abstract][Full Text] [Related]
14. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
[TBL] [Abstract][Full Text] [Related]
15. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5.
Peyronneau MA; Renaud JP; Truan G; Urban P; Pompon D; Mansuy D
Eur J Biochem; 1992 Jul; 207(1):109-16. PubMed ID: 1628642
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
17. No effect of lipoic acid on catalytic activity of cytochrome P450 3A4.
Makhova AA; Shikh EV; Bulko TV; Gilep AA; Usanov SA; Shumyantseva VV
Drug Metab Pers Ther; 2020 Jul; 35(3):. PubMed ID: 32712589
[TBL] [Abstract][Full Text] [Related]
18. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.
Patten CJ; Smith TJ; Friesen MJ; Tynes RE; Yang CS; Murphy SE
Carcinogenesis; 1997 Aug; 18(8):1623-30. PubMed ID: 9276639
[TBL] [Abstract][Full Text] [Related]
19. Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes.
Yamazaki H; Inui Y; Wrighton SA; Guengerich FP; Shimada T
Carcinogenesis; 1995 Sep; 16(9):2167-70. PubMed ID: 7554070
[TBL] [Abstract][Full Text] [Related]
20. [Electroanalytical and electrocatalytical characteristics of cytochrome P450 3A4 using electrodes modified with nanocomposite carbon nanomaterials].
Kuzikov AV; Bulko TV; Koroleva PI; Masamrekh RA; Babkina SS; Gilep AA; Shumyantseva VV
Biomed Khim; 2020 Jan; 66(1):64-70. PubMed ID: 32116227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
